Briefing Paper: Drug Dependence Treatment in China: A Policy Analysis. Tibke P. (2017)

immage

Drug use and supply have been a sensitive and high-priority issue for successive governments in China since at least the Opium Wars in the mid-19th century. China’s policy response to drug use relies on punishment and coercion as central components, including compulsory detoxification, detention in labour camps or so-called ‘rehabilitation’ facilities, and compulsory registration with law enforcement authorities resulting in surveillance and random interrogations. 

 

Yet, in the late-1990s, in a policy move that appeared to emphasize healthcare instead of punishment for people who inject drugs, China began implementing the world’s largest scale-up provision of opioid substitution therapy (OST) and needle and syringe programmes (NSP) – two critical harm reduction measures for preventing HIV transmission. However, the overall approach towards people who use drugs remains punitive and stigmatising in China. As drug use continues to rise and expand across a greater range of drugs (especially synthetic drugs such as methamphetamine), as well as amongst younger age groups, China requires a comprehensive system of evidence-based and humane drug treatment and harm reduction services capable of advancing the health and quality of life of individuals and communities.

 

Keywords: China, HIV, PWID, NSPs and OST, drugs, health, law

 

Download Publication

Patients Helping Patients Understand Opioid Substitution Treatment. Chapman J, Fowler A, Mackenzie B, et al. (2017)

immage

This handbook has been written by a group of patients in British Columbia. We all have long experience with medication-assisted treatments for opioid dependence. The language about drug use is complex. The latest version of the manual that defines diseases and disorders (DSM-V) no longer refers to “dependence” and uses “addiction” instead. In this handbook, we continue to use “dependence” to refer to our experience of “needing the drug” and significant withdrawal symptoms when trying to quit or cut down on our use. Deciding to seek help is an important step in any process of recovery. You are making a wise decision to seek help now. People dependent on opioid drugs and not receiving opioid substitution treatment (OST) are many times more likely to die or be seriously harmed by problem drug use.


Keywords: HIV/AIDS, OST, testing, harm reduction, stigma

 

Download Publication

The Power of Antiretroviral Medicines — 90-90-90 Treatment for All. UNAIDS. (2017)

immage

Saving lives, preventing new HIV infections, preventing mother-to-child transmission of HIV, post-exposure prophylaxis for averting HIV infection, restoring respect and dignity to people living with HIV, pre-exposure prophylaxis for people at higher risk, preventing TB, TB-related deaths and TB transmission, restoring employment, reducing the number of children becoming orphans, and reducing maternal mortality.

 


Keywords: HIV, PMTCT, TB, PrEP, women, children

 

Download Infographic

Global Hepatitis Report, 2017. WHO. (2017)

immage

This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.

 

The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030. 


Keywords: HIV, HCV, HBV, prevention, testing, treatment

 


Download Global Hepatitis Report 2017

 

Download Executive Summary

 

The Journey of Universal Access to Antiretroviral Treatment in Thailand. UNDP, Ministry of Public Health and National Health Security Office. (2017)

immage

This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services

 

Keywords: Thailand, HIV, PLHIV, ART, treatment, health system

 

 

Download Publication 

Global Priority List of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. WHO. (2017)

immage

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.


Keywords: new antibiotics, treatment, drugs, antibiotic resistance

 

Download Publication

Introduction to Long-Acting Injectables. AVAC. (2016)

immage

This infographic details the process for developing long-acting injectables for PrEP and treatment.

 

Keywords: HIV, ARV, PrEP, treatment, prevention, testing

 

Download Infographic

Untangling the Web of Antiretroviral Price Reductions. Medecins Sans Frontieres (MSF). (2016)

immage

The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach. This is in large part because pharmaceutical corporations maintain monopolies that block price-lowering generic competition.

Today, the lowest available price for a quality-assured, World Health Organization-recommended first-line one-pill-a-day combination is US$100 per person per year (tenofovir/emtricitabine/efavirenz). This is a decrease of 26 per cent since MSF last recorded the lowest price for first-line treatment at US$136 in 2014. For a WHO-recommended second-line regimen, the lowest available price is now US$286 per person per year (zidovudine/lamivudine + atazanavir/ritonavir) – an 11 per cent decrease from US$322 two years ago.


Keywords: HIV, ARV, treatment, access, adults, children

 

Download Publication

Policy Brief: WHO Recommends Assistance for People with HIV to Notify their Partners. WHO. (2016)

immage

The sexual partners and drug injecting partners of people diagnosed with HIV infection have an increased probability of also being HIV-positive.
Assisted HIV partner notification services are a simple and effective way to reach these partners, many of whom are undiagnosed and unaware of their HIV exposure, and may welcome support and an opportunity to test for HIV.
Assisted partner notification has been an important public health approach in infectious disease management for decades, including in programmes for sexually transmitted infections and tuberculosis, but has not been routinely implemented for people with HIV.


Keywords: HIV, partner, public health, testing, services

 

Download Publication

 

2016-17: A Percolating Pipeline. AVAC. (2016)

immage

While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.


Keywords: HIV, PrEP,  antibody related, vaccine, microbicides

 

Download Infographic

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Get_on_the_Fast-Track_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NEC_HIV_July-Oct-AIDSreg2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Response_Progress_Reporting_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_AIDS_by_the_numbers_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Biomedical_AIDS_research_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Factsheets.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_Report_Punjab_2014_0.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Integrating_collaborative_TB_and_HIV_services_within_a_comprehensive_package_of_care_for_PWID_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_IBBS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_HSS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/The_negative_impact_of_drug_control_on_public_health_2015.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_young_people_drugs_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Death_Penalty_for_Drug_Offences_Global_Overview_2015.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Transforming_our_world_2015_UN.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Consolidated_Strategic_Information_Guidelines_for_HIV_in_Health_Sector_2015.pdf
Calendar of events
May
17
(17 May - 17 May)
Jul
28
(28 Jul - 28 Jul)